{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"XALience","nct_id":"NCT07213674","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=xalience-nct07213674. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will be randomized to receive xaluritamig in combination with abiraterone acetate.","label":"Xaluritamig Plus Abiraterone","type":"EXPERIMENTAL"},{"description":"Participants will receive investigator's choice of:\n\n* Abiraterone acetate orally, once daily or\n* Docetaxel IV Q3W or\n* Cabazitaxel IV Q3W.","label":"Investigator's Choice","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-08-30","type":"ESTIMATED"},"conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":{"count":750,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Xaluritamig","otherNames":["AMG 509"],"type":"DRUG"},{"name":"Abiraterone acetate","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"},{"name":"Cabazitaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-20","lead_sponsor":"Amgen","official_title":"A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2030-01-07","type":"ESTIMATED"},"primary_outcomes":[{"measure":"OS","timeFrame":"Up to approximately 51 months"}],"references":[],"start_date":{"date":"2025-11-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT07213674"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/xalience-nct07213674"}